Abstract
Rituximab, a genetically engineered monoclonal chimeric antibody, targets the CD20 antigen expressed on B cells. It was approved by the US Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkins lymphoma (LG/F NHL), and by the European Agency for the Evaluation of Medicinal Products on June 2, 1998, for therapy of patients with Stage III/IV, follicular, chemoresistant or relapsed NHL. Eight Phase II or III clinical trials in LG/F NHL patients have been completed five single-agent studies and three combination studies. Rituximab has a favorable safety profile most adverse events (AEs) are Grade 1 or 2, and the frequency of AEs decrease with subsequent infusions. AEs in the combination studies are consistent with those seen with individual agents. For evaluable patients in the single-agent studies, overall response rates (ORR) ranged from 40percent to 60percent, median duration of response (DR) r anged from 5.9 to 15.0+ months, and median time to progression (TTP) ranged from 8.1 to 19.4+ months. For evaluable patients in the combination studies, the ORR ranged from 45percent to 100percent, median DR ranged from 11.7+ to 39.1+ months, and median TTP ranged from 12.9+ to 40.5+ months. Studies in intermediate- and high-grade NHL are ongoing. Long-term development plans include evaluating the safety and efficacy of rituximab in various types of lymphoma and in combination with other lymphoma regimens. Future studies may explore ways to increase rituximab efficacy by upregulating CD20 or increasing effector function with different cytokines.
Keywords: Rituximab, Monoclonal Antibody, Lymphoma, B cell, CD20 positive
Current Pharmaceutical Biotechnology
Title: Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Volume: 1 Issue: 1
Author(s): A. J. Grillo-Lopez, C. A. White, B. K. Dallaire, C. L. Varns, C. D. Shen, A. Wei, J. E. Leonard, A. McClure, R. Weaver, S. Cairelli and J. Rosenberg
Affiliation:
Keywords: Rituximab, Monoclonal Antibody, Lymphoma, B cell, CD20 positive
Abstract: Rituximab, a genetically engineered monoclonal chimeric antibody, targets the CD20 antigen expressed on B cells. It was approved by the US Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkins lymphoma (LG/F NHL), and by the European Agency for the Evaluation of Medicinal Products on June 2, 1998, for therapy of patients with Stage III/IV, follicular, chemoresistant or relapsed NHL. Eight Phase II or III clinical trials in LG/F NHL patients have been completed five single-agent studies and three combination studies. Rituximab has a favorable safety profile most adverse events (AEs) are Grade 1 or 2, and the frequency of AEs decrease with subsequent infusions. AEs in the combination studies are consistent with those seen with individual agents. For evaluable patients in the single-agent studies, overall response rates (ORR) ranged from 40percent to 60percent, median duration of response (DR) r anged from 5.9 to 15.0+ months, and median time to progression (TTP) ranged from 8.1 to 19.4+ months. For evaluable patients in the combination studies, the ORR ranged from 45percent to 100percent, median DR ranged from 11.7+ to 39.1+ months, and median TTP ranged from 12.9+ to 40.5+ months. Studies in intermediate- and high-grade NHL are ongoing. Long-term development plans include evaluating the safety and efficacy of rituximab in various types of lymphoma and in combination with other lymphoma regimens. Future studies may explore ways to increase rituximab efficacy by upregulating CD20 or increasing effector function with different cytokines.
Export Options
About this article
Cite this article as:
Grillo-Lopez J. A., White A. C., Dallaire K. B., Varns L. C., Shen D. C., Wei A., Leonard E. J., McClure A., Weaver R., Cairelli S. and Rosenberg J., Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201003379059
DOI https://dx.doi.org/10.2174/1389201003379059 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer
Current Medicinal Chemistry Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis
Current Medical Imaging Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Photochemotherapy in the Treatment of Cancer
Current Medicinal Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study
Anti-Cancer Agents in Medicinal Chemistry Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) An Update on Poly(ADP-ribose) Polymerase I-A Brief Review
Mini-Reviews in Medicinal Chemistry SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Emerging Immunotargets in Bladder Cancer
Current Drug Targets Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science